Eisai follows family ties with name for newly approved Alzheimer's drug Leqembi
The road to approval for Alzheimer’s drug Leqembi began more than a decade ago when Eisai and Biogen collaborated on a first trial for what was then called BAN2401. The amyloid beta-directed therapy went through years of study before lecanemab became its recommended international non-proprietary (INN) name in September 2020.
Last week, the FDA greenlit the infused drug and it became officially recognized by its proprietary brand Leqembi.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.